Latest Breaking News On - மைக் மக்லேந் - Page 1 : comparemela.com

Avidity Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

Avidity Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesNicholase johnsonAmy conradKathleen gallagherMike macleanEli lillySarah boyceVirginia commonwealth universityPrnewswire avidity biosciences incExchange commissionSociety international research congressDevelopment rd expensesAvidity biosciences incAntibody oligonucleotide conjugatesInvestigational new drugVirginia commonwealth

How Albertans can maintain their health in wildfire smoke

How Albertans can maintain their health in wildfire smoke
cbc.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cbc.ca Daily Mail and Mail on Sunday newspapers.

Fort mcmurrayKerri johanssonSarah hendersonMike macleanDave phillipsHealth campusBc centre for diseaseUniversity of calgarySouth health campusCalgary eyeopeneronDisease controlகோட்டை மக்மரேசாரா ஹென்டர்சன்மைக் மக்லேந்டேவ் பிலிப்ஸ்ஆரோக்கியம் வளாகம்

Avidity Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights

/PRNewswire/ Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody.

United statesPhillipd zamoreAmy conradKathleen gallagherMike macleanEli lillyStevenf dowdySarah boyceTherapeutics instituteExchange commissionDevelopment rd expensesAmerican academy of neurologyAvidity biosciences incAvidity biosciencesAntibody oligonucleotide conjugatesLead program

Avidity Biosciences to Present Oral Presentation on AOC 1001 for DM1 at American Academy of Neurology (AAN) 2021 Virtual Annual Meeting

Avidity Biosciences to Present Oral Presentation on AOC 1001 for DM1 at American Academy of Neurology (AAN) 2021 Virtual Annual Meeting News provided by Share this article Share this article LA JOLLA, Calif., April 16, 2021 /PRNewswire/ Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs ™), today announced that preclinical data for their lead candidate, AOC 1001 in development for myotonic dystrophy type 1 (DM1), will be presented at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting being held April 17-22, 2021. The abstract on AOC 1001 was chosen by the AAN Science Committee as one of 11 abstracts to be highlighted in the Emerging Science Session.

United statesAmy conradMike macleanBarbora malecovaExchange commissionAmerican academy of neurologyScience committeeAvidity biosciences incPrnewswire avidity biosciences incAntibody oligonucleotide conjugatesAmerican academyAnnual meetingEmerging scienceHart levinChief scientificAssociate director

Avidity Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Highlights

Share this article Share this article LA JOLLA, Calif., March 15, 2021 /PRNewswire/ Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2020 and highlighted recent corporate progress. In 2020, we made significant advances across our AOC pipeline and platform. Our work supports Avidity s evolution to a clinical-stage company as we plan to advance AOC 1001 into the clinic in the second half of this year and progress our FSHD and DMD programs, said Sarah Boyce, President and Chief Executive Officer. Our discovery efforts continue to focus on expanding our AOC platform into additional muscle diseases and other tissues as we begin to realize our vision of profoundly improving people s lives by revolutionizing the delivery of RNA treatments.

United statesTamar thompsonJean kimAmy conradMike macleanEli lillyBristol meyers squibbSarah boyceMyotonic dystrophy clinical research networkPrnewswire avidity biosciences incExchange commissionDevelopment rd expensesAvidity biosciences incDiverse team members to managementAntibody oligonucleotide conjugatesChief executive